Alkermes plc (ALKS) P/E Ratio History
Historical price-to-earnings valuation from 2006 to 2026
Loading P/E history...
ALKS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Alkermes plc (ALKS) trades at a price-to-earnings ratio of 24.7x, with a stock price of $35.32 and trailing twelve-month earnings per share of $0.92.
The current P/E is 66% below its 5-year average of 71.8x. Over the past five years, ALKS's P/E has ranged from a low of 8.1x to a high of 467.1x, placing the current valuation at the 70th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ALKS is roughly in line with its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, ALKS trades roughly in line with the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ALKS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ALKS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.8Lowest | 0.66 | +817%Best | |
| $4B | 9.4 | - | +68% | |
| $3B | 18.7 | 0.15Best | +176% | |
| $42B | 30.3 | - | +183% | |
| $2B | 13.1 | - | +431% | |
| $1B | 21.1 | 1.18 | -7% | |
| $2B | 68.5 | - | +194% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ALKS Historical P/E Data (2006–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $35.39 | $0.90 | 39.3x | -49% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $27.98 | $1.43 | 19.6x | -75% |
| FY2025 Q3 | $30.00 | $2.02 | 14.9x | -81% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $28.61 | $2.08 | 13.8x | -82% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $33.02 | $2.09 | 15.8x | -80% |
| FY2024 Q4 | $28.76 | $2.17 | 13.3x | -83% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $27.99 | $1.95 | 14.4x | -81% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $24.10 | $1.68 | 14.3x | -81% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $27.07 | $2.53 | 10.7x | -86% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $27.74 | $2.07 | 13.4x | -83% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $28.01 | $1.24 | 22.6x | -71% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $31.30 | $0.57 | 54.9x | -29% |
Average P/E for displayed period: 77.1x
See ALKS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALKS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALKS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALKS — Frequently Asked Questions
Quick answers to the most common questions about buying ALKS stock.
Is ALKS stock overvalued or undervalued?
ALKS trades at 24.7x P/E, below its 5-year average of 71.8x. At the 70th percentile of historical range, the stock is priced at a discount to its own history.
How does ALKS's valuation compare to peers?
Alkermes plc P/E of 24.7x compares to sector median of 22.1x. The premium reflects expected growth above peers.
What is ALKS's PEG ratio?
ALKS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2006-2026.